Carrier-Free Nanoprodrug Mediating Laser-Activable Chemotherapeutic Immunomodulation against Cancer
ACS Nano · 2025-09-09 · 19 (35) · 31582-31597
DOI: 10.1021/acsnano.5c08856 ↗At a glance
Journal article in ACS Nano, published online on 2025-08-28. Written by Di Gao and 10 co-authors. Institution: The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, …. Major MEDLINE topics: Prodrugs, Photosensitizing Agents, Deoxycytidine, Immunomodulation. Cited 11 times so far (Crossref); 40 references. Funded by: China Postdoctoral Science Foundation, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (original language)
Gemcitabine (GEM), an "old-school" chemotherapeutic agent, holds significant potential for repurposing due to its immunomodulatory properties, particularly in mitigating the immunosuppressive tumor microenvironment by depleting myeloid-derived suppressor cells and regulatory T cells. However, it is not regarded as an immunogenic agent, leaving a "cold" tumor state. Thus, we developed a carrier-free nanoprodrug that self-assembles from two zinc phthalocyanine (ZnPc)-based photosensitizer prodrugs, incorporating photodynamic therapy (PDT) to induce immunogenic cell death. A reactive oxygen species (ROS)-cleavable β-aminoacrylate linker (AA) was utilized to conjugate ZnPc and GEM, synthesizing the prodrug ZnPc-AA-GEM, which enables GEM release following ROS generation induced by PDT. Furthermore, the amphiphilic ZnPc-PEG enhances the stability and circulation time of the nanoprodrugs. These nanoprodrugs facilitate efficient tumor accumulation of GEM, activating its function through laser irradiation. Importantly, the combination of PDT and GEM increases tumor immunogenicity, enhancing effector T cell recruitment and mitigating tumor-associated immunosuppression, thereby amplifying the chemotherapeutic immunomodulatory effects of GEM. Comprehensive biosecurity evaluations indicated that carrier-free nanoprodrug exhibits minimal hemotoxicity and no significant adverse effects. Our study proposes a strategy that leverages traditional chemotherapeutics alongside advanced photodynamic approaches for more effective cancer treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 710049, China.
- Research Institute of Xi'an Jiaotong University, Hangzhou 311200, China.
ORCID profiles: Zhongmin Tian, Zhe Yang
Funding
- China Postdoctoral Science Foundation
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Natural Science Foundation of Shaanxi Province
- Natural Science Foundation of Zhejiang Province
- Postdoctoral Science Foundation of Shaanxi Province
- Shaanxi Province
Cite
APA
Gao, D., He, X., Jia, L., Zhang, X., Ren, L., Ren, X., Liu, X., Yun, R., Hu, Z., Tian, Z., & Yang, Z. (2025). Carrier-Free Nanoprodrug Mediating Laser-Activable Chemotherapeutic Immunomodulation against Cancer. ACS Nano, 19(35), 31582-31597. https://doi.org/10.1021/acsnano.5c08856
Vancouver
Gao D, He X, Jia L, Zhang X, Ren L, Ren X, et al. Carrier-Free Nanoprodrug Mediating Laser-Activable Chemotherapeutic Immunomodulation against Cancer. ACS Nano. 2025;19(35):31582-31597. doi:10.1021/acsnano.5c08856
BibTeX
@article{Gao2025,
author = {Gao, Di and He, Xinyu and Jia, Liangliang and Zhang, Xinyuan and Ren, Liujiao and Ren, Xuechun and Liu, Xinyang and Yun, Rong and Hu, Zeyu and Tian, Zhongmin and Yang, Zhe},
title = {Carrier-Free Nanoprodrug Mediating Laser-Activable Chemotherapeutic Immunomodulation against Cancer},
journal = {ACS Nano},
year = {2025},
volume = {19},
number = {35},
pages = {31582--31597},
doi = {10.1021/acsnano.5c08856}
}
EUVIMED